DK3497086T3 - Aminopyrimidin-SSAO-inhibitorer - Google Patents

Aminopyrimidin-SSAO-inhibitorer Download PDF

Info

Publication number
DK3497086T3
DK3497086T3 DK17838647.0T DK17838647T DK3497086T3 DK 3497086 T3 DK3497086 T3 DK 3497086T3 DK 17838647 T DK17838647 T DK 17838647T DK 3497086 T3 DK3497086 T3 DK 3497086T3
Authority
DK
Denmark
Prior art keywords
aminopyrimidine
ssao inhibitors
ssao
inhibitors
aminopyrimidine ssao
Prior art date
Application number
DK17838647.0T
Other languages
English (en)
Inventor
David Andrew Coates
Luo Heng Qin
Yi Wei
Jingye Zhou
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3497086T3 publication Critical patent/DK3497086T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK17838647.0T 2016-08-12 2017-08-04 Aminopyrimidin-SSAO-inhibitorer DK3497086T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2016/094833 WO2018027892A1 (en) 2016-08-12 2016-08-12 Amino pyrimidine ssao inhibitors
PCT/CN2017/095999 WO2018028517A1 (en) 2016-08-12 2017-08-04 Amino pyrimidine ssao inhibitors

Publications (1)

Publication Number Publication Date
DK3497086T3 true DK3497086T3 (da) 2022-03-14

Family

ID=61161335

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17838647.0T DK3497086T3 (da) 2016-08-12 2017-08-04 Aminopyrimidin-SSAO-inhibitorer
DK21206067.7T DK3984996T3 (da) 2016-08-12 2017-08-04 Aminopyridin-SSAO-inhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21206067.7T DK3984996T3 (da) 2016-08-12 2017-08-04 Aminopyridin-SSAO-inhibitorer

Country Status (22)

Country Link
US (3) US10287270B2 (da)
EP (3) EP3984996B1 (da)
JP (2) JP7035013B2 (da)
KR (3) KR20240035917A (da)
CN (2) CN108884056B (da)
AU (2) AU2017309199B2 (da)
CA (1) CA3033687A1 (da)
CR (1) CR20190124A (da)
DK (2) DK3497086T3 (da)
ES (2) ES2908805T3 (da)
HU (1) HUE058142T2 (da)
IL (1) IL264745B (da)
MA (1) MA45937A (da)
MX (1) MX389672B (da)
MY (1) MY196576A (da)
NZ (1) NZ750290A (da)
PH (1) PH12019500296A1 (da)
PL (2) PL3984996T3 (da)
PT (1) PT3497086T (da)
SG (1) SG11201900844UA (da)
WO (2) WO2018027892A1 (da)
ZA (2) ZA201901097B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
CN109810041B (zh) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
CN110938059A (zh) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) * 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
SG11202102440SA (en) 2018-10-29 2021-04-29 Boehringer Ingelheim Int Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
TW202039486A (zh) * 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
TWI835945B (zh) * 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
US12371432B2 (en) * 2019-01-11 2025-07-29 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
BR112022007974A2 (pt) 2019-10-29 2022-07-12 Eccogene Shanghai Co Ltd Inibidores de ssao e uso dos mesmos
CN113149957A (zh) * 2020-01-23 2021-07-23 轶诺(浙江)药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
US20230127498A1 (en) * 2020-03-25 2023-04-27 Terns, Inc. Treatment of respiratory disorders
US20210379040A1 (en) * 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
WO2022046779A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
CN114621243B (zh) * 2020-12-14 2024-03-01 上海拓界生物医药科技有限公司 一种磺酰胺类衍生物及其用途
KR20220145981A (ko) * 2021-04-22 2022-11-01 주식회사유한양행 트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물
AU2022387121A1 (en) * 2021-11-11 2024-06-20 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
US20230181583A1 (en) * 2021-11-11 2023-06-15 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120528A2 (en) * 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
WO2008123469A1 (ja) * 2007-03-30 2008-10-16 Japan Tobacco Inc. 6員環アミド化合物およびその用途
JP2010533658A (ja) 2007-07-20 2010-10-28 メルク フロスト カナダ リミテツド ステアロイル補酵素aデルタ−9デサチュラーゼ阻害剤としての二環性へテロ芳香族化合物
CA2706465A1 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
JP2011136942A (ja) * 2009-12-28 2011-07-14 Kowa Co 新規な置換ピリミジン誘導体およびこれを含有する医薬
EA024102B1 (ru) 2011-03-15 2016-08-31 Астеллас Фарма Инк. Гуанидиновые соединения, полезные для предотвращения и/или лечения диабетической нефропатии или диабетического отека желтого пятна
SI2844637T1 (en) * 2012-05-02 2018-07-31 Boehringer Ingelheim International Gmbh Substituted 3-haloallylamine inhibitors of ssao and uses thereof
BR112015010649A2 (pt) * 2012-11-16 2017-07-11 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina
US8962641B2 (en) * 2013-04-17 2015-02-24 Boehringer Ingelheim International Gmbh Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
JP6378752B2 (ja) * 2013-05-17 2018-08-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピロリジン誘導体、その医薬組成物及び使用
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors

Also Published As

Publication number Publication date
AU2022203071A1 (en) 2022-05-26
PT3497086T (pt) 2022-03-14
EP3497086B1 (en) 2021-12-15
US10464928B2 (en) 2019-11-05
ZA202202097B (en) 2023-11-29
EP3984996B1 (en) 2024-10-09
WO2018028517A1 (en) 2018-02-15
MY196576A (en) 2023-04-19
CN114380801B (zh) 2025-07-29
HUE058142T2 (hu) 2022-07-28
KR102646063B1 (ko) 2024-03-12
CR20190124A (es) 2019-05-13
JP2019527717A (ja) 2019-10-03
MX389672B (es) 2025-03-20
JP2022003049A (ja) 2022-01-11
AU2017309199A1 (en) 2019-02-21
US20190276436A1 (en) 2019-09-12
PL3497086T3 (pl) 2022-05-02
ZA201901097B (en) 2022-08-31
KR20230008889A (ko) 2023-01-16
JP7035013B2 (ja) 2022-03-14
EP3497086A4 (en) 2020-03-25
ES2992165T3 (es) 2024-12-09
ES2908805T3 (es) 2022-05-04
KR20190038580A (ko) 2019-04-08
IL264745B (en) 2021-08-31
EP4501323A3 (en) 2025-03-19
CN108884056B (zh) 2022-01-07
CN114380801A (zh) 2022-04-22
US20200262817A1 (en) 2020-08-20
SG11201900844UA (en) 2019-02-27
AU2017309199B2 (en) 2022-05-12
EP3497086A1 (en) 2019-06-19
US10287270B2 (en) 2019-05-14
CN108884056A (zh) 2018-11-23
KR102483876B1 (ko) 2023-01-03
BR112019002275A2 (pt) 2019-06-18
EP4501323A2 (en) 2025-02-05
EP3984996A1 (en) 2022-04-20
MA45937A (fr) 2019-06-19
MX2019001581A (es) 2019-06-20
AU2022203071B2 (en) 2024-06-20
PL3984996T3 (pl) 2025-03-10
JP7372957B2 (ja) 2023-11-01
US10793552B2 (en) 2020-10-06
US20180297987A1 (en) 2018-10-18
KR20240035917A (ko) 2024-03-18
WO2018027892A1 (en) 2018-02-15
NZ750290A (en) 2022-09-30
DK3984996T3 (da) 2024-10-21
CA3033687A1 (en) 2018-02-15
PH12019500296A1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
FIC20240013I1 (fi) Lebrikitsumabi
IL269196A (en) Novel inhibitors
IL263586A (en) Inhibitors of the menin-mll interaction
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
IL280863A (en) Autotaxin inhibitors and uses thereof
EP3626699A4 (en) SSAO INHIBITOR
DK3984996T3 (da) Aminopyridin-SSAO-inhibitorer
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
LT3303334T (lt) Tirozinkinazės inhibitoriai
EP3522831C0 (en) NEO-PHALLUS IMPLANT
PL3657060T3 (pl) Zacisk
LT3371171T (lt) Ret inhibitoriai
DK3571192T3 (da) Jak1-selektive inhibitorer
EP3440949A4 (en) FLAVOR INHALER
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
EP3347008A4 (en) BETA-Lactamase INHIBITORS
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3341379T3 (da) EZH2-hæmmere
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
EP3402423C0 (fr) Dispositif d'implant